Difference between revisions of "Neuroblastoma"
Jump to navigation
Jump to search
| Line 18: | Line 18: | ||
=High-risk= | =High-risk= | ||
| − | ==Dinutuximab, GM-CSF, IL-2, and Isotretinoin== | + | ==Dinutuximab, GM-CSF, IL-2, and Isotretinoin {{#subobject:231faf|Regimen=1}}== |
''Phase III results announced but no trial published in the peer-reviewed literature, yet.'' | ''Phase III results announced but no trial published in the peer-reviewed literature, yet.'' | ||
===References=== | ===References=== | ||
# Dinutuximab Approved for High-Risk Neuroblastoma. Cancer Discov. 2015 Apr 7. [Epub ahead of print] [http://cancerdiscovery.aacrjournals.org/content/early/2015/04/07/2159-8290.CD-NB2015-044.long link to article] [http://www.ncbi.nlm.nih.gov/pubmed/25851859 PubMed] | # Dinutuximab Approved for High-Risk Neuroblastoma. Cancer Discov. 2015 Apr 7. [Epub ahead of print] [http://cancerdiscovery.aacrjournals.org/content/early/2015/04/07/2159-8290.CD-NB2015-044.long link to article] [http://www.ncbi.nlm.nih.gov/pubmed/25851859 PubMed] | ||
Revision as of 16:18, 21 May 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
14 regimens on this page
15 variants on this page
|
Neuroblastoma is a rare cancer but is the most common malignancy of infancy. Most of our contributors are adult oncologists, please consider expanding this page!
Low-risk
Intermediate-risk
High-risk
Dinutuximab, GM-CSF, IL-2, and Isotretinoin
Phase III results announced but no trial published in the peer-reviewed literature, yet.
References
- Dinutuximab Approved for High-Risk Neuroblastoma. Cancer Discov. 2015 Apr 7. [Epub ahead of print] link to article PubMed